万春医药上涨4.35%，报2.16美元/股，总市值8708.33万美元

Core Insights - BeyondSpring Pharmaceuticals (BYSI) opened with a 4.35% increase on August 5, trading at $2.16 per share, with a total market capitalization of $87.083 million [1] - As of June 30, 2024, the company reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through unique academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, targeting areas such as non-small cell lung cancer and the prevention of neutropenia [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2]